Accelerate Diagnostics (AXDX) Reports In-Line Q3 EPS

Accelerate Diagnostics (NASDAQ: AXDX) reported Q3 EPS of ($0.41), in-line with the analyst estimate of ($0.41). Revenue for the quarter came in at $1.36 million versus the consensus estimate of $2.95 million.

For earnings history and earnings-related data on Accelerate Diagnostics (AXDX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'
• The LGL Group (LGL) Misses Q2 EPS by 8c